Pathological outcomes of HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab or dual anti-HER2 therapy and carboplatin with docetaxel: A Maria Sklodowska-Curie National Research Institute of Oncology experience.

Agnieszka Jagiełło-Gruszfeld,I. Lemanska,R. Sienkiewicz,Ewa Szombara,Roman Dubiański,Elzbieta Brewczynska,Katarzyna Pogoda,Aleksandra Konieczna,Michał Kunkiel,Anna Majstrak-Hulewska,Wojciech P. Olszewski,Anna Niwińska,Zbigniew I. Nowecki

Pathological outcomes of HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab or dual anti-HER2 therapy and carboplatin with docetaxel: A Maria Sklodowska-Curie National Research Institute of Oncology experience.

2020

Agnieszka Jagiełło-Gruszfeld
I. Lemanska
R. Sienkiewicz
Ewa Szombara
Roman Dubiański
Elzbieta Brewczynska
Katarzyna Pogoda
Aleksandra Konieczna
Michał Kunkiel
Anna Majstrak-Hulewska
Wojciech P. Olszewski
Anna Niwińska
Zbigniew I. Nowecki

e12655Background: Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) for breast cancer predicts the risk of recurrence and increasingly may indicate the need for additional ...

Keywords:

Trastuzumab
Oncology
early breast cancer
Pathological
Carboplatin
Curie
Internal medicine
anti her2
Docetaxel
Medicine
Breast cancer
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations